By contrast, there was no increase in stromal Cox-2 immunoreactivity in transgenic cLys-Cox-2 x ApcMin/+ mouse tumours anywhere in the SI compared with non-transgenic ApcMin/+ mouse SI tumours (median [inter-quartile range] non-transgenic Cox-2 score 21–3 for n = 27 versus transgenic Cox-2 score 11–3 for n = 25; P = 0.29, Mann-Whitney U test). Here, PTGS2 is linked to neoplasm.